Barbara C. Fullerton, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Evoked Potentials, Auditory, Brain Stem | 8 | 2005 | 249 | 0.510 |
Why?
|
Chordoma | 6 | 2023 | 359 | 0.460 |
Why?
|
Skull Base Neoplasms | 5 | 2023 | 277 | 0.440 |
Why?
|
Photons | 7 | 2018 | 592 | 0.420 |
Why?
|
Chondrosarcoma | 6 | 2023 | 310 | 0.320 |
Why?
|
Auditory Pathways | 6 | 2005 | 234 | 0.310 |
Why?
|
Radiation Injuries | 6 | 2021 | 1161 | 0.290 |
Why?
|
Radiotherapy, Conformal | 6 | 2013 | 548 | 0.270 |
Why?
|
Inferior Colliculi | 3 | 2005 | 68 | 0.260 |
Why?
|
Cochlear Nucleus | 2 | 2005 | 62 | 0.260 |
Why?
|
Olivary Nucleus | 2 | 2005 | 130 | 0.250 |
Why?
|
Brain Stem | 10 | 2000 | 849 | 0.250 |
Why?
|
Auditory Cortex | 2 | 2007 | 344 | 0.240 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 9 | 2021 | 1625 | 0.240 |
Why?
|
Meningioma | 3 | 2019 | 1202 | 0.230 |
Why?
|
Meningeal Neoplasms | 3 | 2019 | 1234 | 0.220 |
Why?
|
Protons | 5 | 2023 | 1124 | 0.210 |
Why?
|
Relative Biological Effectiveness | 2 | 2021 | 323 | 0.210 |
Why?
|
Temporal Lobe | 2 | 2007 | 1671 | 0.200 |
Why?
|
Cranial Irradiation | 3 | 2019 | 402 | 0.190 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2021 | 802 | 0.180 |
Why?
|
Radiotherapy Dosage | 11 | 2021 | 2872 | 0.170 |
Why?
|
Lymphoma, Extranodal NK-T-Cell | 1 | 2019 | 43 | 0.170 |
Why?
|
Neuroma, Acoustic | 1 | 2022 | 449 | 0.160 |
Why?
|
Neurosecretory Systems | 1 | 2019 | 230 | 0.150 |
Why?
|
Optic Nerve | 2 | 2018 | 558 | 0.150 |
Why?
|
Hypopituitarism | 1 | 2019 | 254 | 0.140 |
Why?
|
Glioma | 3 | 2019 | 3378 | 0.140 |
Why?
|
Carotid Stenosis | 1 | 2023 | 851 | 0.130 |
Why?
|
Supratentorial Neoplasms | 2 | 2013 | 160 | 0.130 |
Why?
|
Optic Nerve Diseases | 1 | 2018 | 326 | 0.130 |
Why?
|
Hearing Loss | 1 | 2022 | 759 | 0.120 |
Why?
|
Organs at Risk | 2 | 2018 | 347 | 0.120 |
Why?
|
Cerebellar Neoplasms | 2 | 2013 | 582 | 0.120 |
Why?
|
Brain Neoplasms | 5 | 2019 | 8791 | 0.120 |
Why?
|
Medulloblastoma | 2 | 2013 | 677 | 0.120 |
Why?
|
Auditory Perception | 6 | 1998 | 567 | 0.110 |
Why?
|
Radiosurgery | 1 | 2022 | 1305 | 0.110 |
Why?
|
Pituitary Neoplasms | 1 | 2021 | 1334 | 0.110 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2013 | 140 | 0.110 |
Why?
|
Cats | 4 | 1996 | 1000 | 0.100 |
Why?
|
Rhabdoid Tumor | 1 | 2013 | 211 | 0.100 |
Why?
|
Memory Disorders | 1 | 2018 | 1183 | 0.090 |
Why?
|
Pituitary Gland | 3 | 2019 | 667 | 0.090 |
Why?
|
Teratoma | 1 | 2013 | 386 | 0.090 |
Why?
|
Radiation Tolerance | 2 | 2018 | 486 | 0.090 |
Why?
|
Head and Neck Neoplasms | 1 | 2023 | 2706 | 0.080 |
Why?
|
Pons | 4 | 2000 | 244 | 0.080 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2012 | 545 | 0.080 |
Why?
|
Postmortem Changes | 1 | 2007 | 125 | 0.080 |
Why?
|
Sound Localization | 2 | 2000 | 60 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2017 | 9122 | 0.080 |
Why?
|
Multiple Sclerosis | 6 | 2000 | 3065 | 0.070 |
Why?
|
Macaca | 1 | 2007 | 443 | 0.070 |
Why?
|
Cauda Equina | 1 | 2005 | 39 | 0.070 |
Why?
|
Hippocampus | 1 | 2018 | 3657 | 0.070 |
Why?
|
Acoustic Stimulation | 4 | 2005 | 1216 | 0.060 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2010 | 480 | 0.060 |
Why?
|
Skull Neoplasms | 2 | 2018 | 173 | 0.060 |
Why?
|
Ependymoma | 1 | 2008 | 333 | 0.060 |
Why?
|
Central Nervous System Neoplasms | 1 | 2013 | 894 | 0.060 |
Why?
|
Evoked Potentials, Auditory | 1 | 1987 | 525 | 0.060 |
Why?
|
Neoplasms, Second Primary | 1 | 2012 | 1045 | 0.060 |
Why?
|
Adult | 23 | 2023 | 213394 | 0.060 |
Why?
|
Staining and Labeling | 1 | 2007 | 1108 | 0.060 |
Why?
|
Noise | 1 | 2005 | 278 | 0.060 |
Why?
|
Male | 29 | 2021 | 349022 | 0.060 |
Why?
|
Orbital Neoplasms | 1 | 2005 | 226 | 0.060 |
Why?
|
Functional Laterality | 2 | 2007 | 2291 | 0.050 |
Why?
|
Stroke | 2 | 2023 | 9898 | 0.050 |
Why?
|
Rhabdomyosarcoma | 1 | 2005 | 381 | 0.050 |
Why?
|
Child, Preschool | 8 | 2023 | 40802 | 0.050 |
Why?
|
Treatment Outcome | 8 | 2023 | 62693 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 9 | 2005 | 35326 | 0.050 |
Why?
|
Cognition | 2 | 2018 | 6686 | 0.050 |
Why?
|
Follow-Up Studies | 6 | 2023 | 38942 | 0.050 |
Why?
|
Skull Base | 1 | 2023 | 296 | 0.050 |
Why?
|
Humans | 38 | 2023 | 739398 | 0.050 |
Why?
|
Female | 28 | 2021 | 378853 | 0.050 |
Why?
|
Radiometry | 2 | 2018 | 801 | 0.040 |
Why?
|
Disease-Free Survival | 3 | 2017 | 6871 | 0.040 |
Why?
|
Ear | 1 | 2000 | 171 | 0.040 |
Why?
|
Infant | 6 | 2023 | 34923 | 0.040 |
Why?
|
Brain | 5 | 2021 | 26345 | 0.040 |
Why?
|
Prospective Studies | 7 | 2022 | 53037 | 0.040 |
Why?
|
Adolescent | 11 | 2023 | 85405 | 0.040 |
Why?
|
Infratentorial Neoplasms | 2 | 2013 | 94 | 0.040 |
Why?
|
Child | 9 | 2023 | 77033 | 0.040 |
Why?
|
Hearing | 1 | 2022 | 478 | 0.040 |
Why?
|
Skull | 1 | 2023 | 809 | 0.040 |
Why?
|
Thyroid Function Tests | 1 | 2019 | 284 | 0.040 |
Why?
|
Craniopharyngioma | 1 | 2021 | 281 | 0.040 |
Why?
|
Moyamoya Disease | 1 | 2021 | 235 | 0.040 |
Why?
|
Nausea | 1 | 2021 | 656 | 0.040 |
Why?
|
Brain Mapping | 2 | 2007 | 6666 | 0.040 |
Why?
|
Vomiting | 1 | 2021 | 622 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2017 | 423 | 0.030 |
Why?
|
Kainic Acid | 1 | 1996 | 198 | 0.030 |
Why?
|
Excitatory Amino Acid Agonists | 1 | 1996 | 147 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2008 | 877 | 0.030 |
Why?
|
Mental Processes | 1 | 1997 | 249 | 0.030 |
Why?
|
Monte Carlo Method | 1 | 2021 | 1279 | 0.030 |
Why?
|
Hypothalamus | 1 | 2001 | 1066 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1904 | 0.030 |
Why?
|
Cerebral Infarction | 1 | 2000 | 1004 | 0.030 |
Why?
|
Middle Aged | 16 | 2019 | 212863 | 0.030 |
Why?
|
Aged | 10 | 2019 | 162698 | 0.030 |
Why?
|
Young Adult | 5 | 2023 | 56255 | 0.030 |
Why?
|
Retrospective Studies | 7 | 2022 | 76631 | 0.030 |
Why?
|
Vision Disorders | 1 | 2021 | 1058 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1524 | 0.030 |
Why?
|
Echo-Planar Imaging | 1 | 1998 | 658 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2005 | 12237 | 0.030 |
Why?
|
Headache | 1 | 2021 | 1199 | 0.030 |
Why?
|
Chondroma | 1 | 1992 | 58 | 0.030 |
Why?
|
Cranial Nerves | 1 | 1992 | 97 | 0.020 |
Why?
|
Cerebrovascular Disorders | 1 | 1998 | 1497 | 0.020 |
Why?
|
Radiotherapy, High-Energy | 1 | 1992 | 228 | 0.020 |
Why?
|
Endocrine System Diseases | 1 | 2013 | 248 | 0.020 |
Why?
|
Germinoma | 1 | 2010 | 133 | 0.020 |
Why?
|
Cochlear Nerve | 1 | 1990 | 197 | 0.020 |
Why?
|
Memory | 1 | 2018 | 2161 | 0.020 |
Why?
|
Reaction Time | 3 | 1998 | 2097 | 0.020 |
Why?
|
Cochlea | 2 | 2012 | 830 | 0.020 |
Why?
|
Survival Rate | 3 | 2010 | 12761 | 0.020 |
Why?
|
Electrophysiology | 3 | 1996 | 1309 | 0.020 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2013 | 767 | 0.020 |
Why?
|
Body Height | 1 | 2013 | 1577 | 0.020 |
Why?
|
Quality of Life | 2 | 2019 | 12640 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 2005 | 377 | 0.020 |
Why?
|
Stapedius | 1 | 1985 | 24 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2018 | 6963 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2013 | 3453 | 0.020 |
Why?
|
Prognosis | 2 | 2019 | 28901 | 0.020 |
Why?
|
Psychoacoustics | 2 | 1995 | 56 | 0.020 |
Why?
|
Brain Ischemia | 1 | 1998 | 3246 | 0.020 |
Why?
|
Animals | 7 | 2007 | 168368 | 0.020 |
Why?
|
Species Specificity | 1 | 1987 | 2480 | 0.010 |
Why?
|
Facial Nerve | 1 | 1985 | 259 | 0.010 |
Why?
|
Cause of Death | 1 | 2013 | 3564 | 0.010 |
Why?
|
Auditory Threshold | 2 | 1995 | 364 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13237 | 0.010 |
Why?
|
Treatment Failure | 1 | 2008 | 2614 | 0.010 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2005 | 334 | 0.010 |
Why?
|
Aged, 80 and over | 4 | 2019 | 57650 | 0.010 |
Why?
|
Neurons | 2 | 1996 | 9336 | 0.010 |
Why?
|
Incidence | 1 | 2018 | 20913 | 0.010 |
Why?
|
Hyperprolactinemia | 1 | 2001 | 129 | 0.010 |
Why?
|
Muscles | 1 | 1985 | 1608 | 0.010 |
Why?
|
Motor Neurons | 1 | 1985 | 843 | 0.010 |
Why?
|
Fetal Hypoxia | 1 | 1979 | 29 | 0.010 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 1987 | 1539 | 0.010 |
Why?
|
Risk | 1 | 2012 | 9684 | 0.010 |
Why?
|
Dichotic Listening Tests | 1 | 1998 | 22 | 0.010 |
Why?
|
Asphyxia Neonatorum | 1 | 1979 | 106 | 0.010 |
Why?
|
Spinal Neoplasms | 1 | 2005 | 758 | 0.010 |
Why?
|
Discrimination Learning | 1 | 1979 | 280 | 0.010 |
Why?
|
Nissl Bodies | 1 | 1996 | 16 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2005 | 6370 | 0.010 |
Why?
|
Neuropsychology | 1 | 1997 | 109 | 0.010 |
Why?
|
Hypothyroidism | 1 | 2001 | 659 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 40050 | 0.010 |
Why?
|
Hypogonadism | 1 | 2001 | 792 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2013 | 25470 | 0.010 |
Why?
|
Audiometry | 1 | 1995 | 241 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2004 | 5058 | 0.010 |
Why?
|
Axons | 2 | 1996 | 1689 | 0.010 |
Why?
|
Cranial Nerve Injuries | 1 | 1992 | 25 | 0.010 |
Why?
|
Risk Factors | 1 | 2018 | 71974 | 0.010 |
Why?
|
Reference Values | 1 | 1998 | 4983 | 0.010 |
Why?
|
Speech Perception | 1 | 1994 | 487 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13635 | 0.010 |
Why?
|
Cricetinae | 1 | 1993 | 2468 | 0.010 |
Why?
|
Psychomotor Performance | 1 | 1997 | 1899 | 0.010 |
Why?
|
Learning | 1 | 1997 | 1695 | 0.000 |
Why?
|
Heart Rate | 1 | 1998 | 4095 | 0.000 |
Why?
|
Models, Neurological | 1 | 1995 | 1769 | 0.000 |
Why?
|
Combined Modality Therapy | 1 | 1998 | 8605 | 0.000 |
Why?
|
Chorda Tympani Nerve | 1 | 1985 | 15 | 0.000 |
Why?
|
Nerve Endings | 1 | 1983 | 109 | 0.000 |
Why?
|
Vagus Nerve | 1 | 1985 | 432 | 0.000 |
Why?
|
Cell Count | 1 | 1985 | 1833 | 0.000 |
Why?
|
Microscopy, Electron | 1 | 1983 | 2665 | 0.000 |
Why?
|
Nerve Fibers | 1 | 1983 | 689 | 0.000 |
Why?
|
Haplorhini | 1 | 1979 | 558 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2001 | 20055 | 0.000 |
Why?
|
Synapses | 1 | 1983 | 1719 | 0.000 |
Why?
|
Evoked Potentials | 1 | 1979 | 1057 | 0.000 |
Why?
|
Macaca mulatta | 1 | 1979 | 2384 | 0.000 |
Why?
|
Pregnancy | 1 | 1979 | 29002 | 0.000 |
Why?
|